HSK16149，probenecid, cimetidine
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PHN - Post-Herpetic Neuritis
Conditions
PHN - Post-Herpetic Neuritis
Trial Timeline
Mar 20, 2023 → Jun 5, 2023
NCT ID
NCT05881811About HSK16149，probenecid, cimetidine
HSK16149，probenecid, cimetidine is a phase 1 stage product being developed by Haisco Pharmaceutical Group for PHN - Post-Herpetic Neuritis. The current trial status is completed. This product is registered under clinical trial identifier NCT05881811. Target conditions include PHN - Post-Herpetic Neuritis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05881811 | Phase 1 | Completed |
Competing Products
5 competing products in PHN - Post-Herpetic Neuritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 23 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 52 |
| EMA401 + Placebo | Novartis | Phase 2 | 52 |
| pregabalin | Pfizer | Approved | 84 |
| BMS-954561 + BMS-954561 + Placebo | Bristol Myers Squibb | Phase 2 | 51 |